Hyperamylasemia During Omalizumab Therapy

Karabiber, E; Ozturk Aktas, O; Ozdemir, E; Damadoglu, E; Sahiner, UM; Karakaya, G; Kalyoncu, AF

Karabiber, E (通讯作者),Marmara Univ Pendik Training & Res Hosp, Dept Immunol & Allergy Dis, Istanbul, Turkey.

ASTIM ALLERJI IMMUNOLOJI, 2022; 20 (1): 31

Abstract

Objective: Omalizumab safety studies have shown that the drug has an excellent safety profile and is well tolerated in patients with asthma and chroni......

Full Text Link